InvestorsHub Logo
Followers 2
Posts 133
Boards Moderated 0
Alias Born 11/12/2010

Re: None

Sunday, 03/23/2014 8:07:03 PM

Sunday, March 23, 2014 8:07:03 PM

Post# of 3108
Gamida Cell receives buyout offer
that could reach hundreds of millions of dollars
Sources say Swiss drugmaker Novartis made the bid for the Israeli startup that specializes in stem cell medical technology.
By Yoram Gabison | Mar. 19, 2014 | 2:44 AM
http://www.haaretz.com/business/.premium-1.580557

NBS will be next when the results of the Baxter RENEW and Neostem PRESERVE studies are completed around July of this year with excellent results. I expect the Baxter tender offer to be between $15 - 20 per share. In the long run it may be cheaper for Baxter to buy out NBS than pay NBS for the CD 34 stem cells it buys from the NBS subsidiary of PCT.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LSTA News